Royalty Pharma PLC (NASDAQ:RPRX) Holdings Raised by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. increased its position in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 14.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 627,048 shares of the biopharmaceutical company's stock after acquiring an additional 78,287 shares during the period. Robeco Institutional Asset Management B.V. owned about 0.11% of Royalty Pharma worth $19,520,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Adage Capital Partners GP L.L.C. lifted its position in shares of Royalty Pharma by 42.6% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 16,968,321 shares of the biopharmaceutical company's stock worth $432,862,000 after buying an additional 5,069,127 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Royalty Pharma by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 7,312,551 shares of the biopharmaceutical company's stock worth $186,846,000 after purchasing an additional 46,765 shares in the last quarter. Norges Bank acquired a new stake in Royalty Pharma during the 4th quarter valued at $124,498,000. Two Sigma Advisers LP boosted its holdings in Royalty Pharma by 21.1% in the fourth quarter. Two Sigma Advisers LP now owns 3,673,200 shares of the biopharmaceutical company's stock valued at $93,703,000 after acquiring an additional 640,000 shares during the last quarter. Finally, Northern Trust Corp raised its stake in shares of Royalty Pharma by 12.8% during the fourth quarter. Northern Trust Corp now owns 3,330,429 shares of the biopharmaceutical company's stock worth $84,959,000 after buying an additional 376,619 shares during the last quarter. 54.35% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on RPRX. Citigroup reaffirmed a "buy" rating on shares of Royalty Pharma in a research note on Friday, March 28th. Wall Street Zen lowered Royalty Pharma from a "buy" rating to a "hold" rating in a report on Sunday. Finally, Morgan Stanley initiated coverage on shares of Royalty Pharma in a research report on Friday, May 16th. They issued an "overweight" rating and a $51.00 target price for the company. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $47.33.

Royalty Pharma Stock Up 1.7%

Royalty Pharma stock opened at $35.87 on Friday. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.56 and a quick ratio of 1.56. The company's 50-day moving average is $33.47 and its 200-day moving average is $31.59. The firm has a market capitalization of $20.17 billion, a PE ratio of 19.39, a P/E/G ratio of 1.84 and a beta of 0.48. Royalty Pharma PLC has a fifty-two week low of $24.05 and a fifty-two week high of $36.32.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.99 by $0.07. The company had revenue of $839.00 million during the quarter, compared to analysts' expectations of $724.69 million. Royalty Pharma had a net margin of 48.23% and a return on equity of 24.71%. Sell-side analysts anticipate that Royalty Pharma PLC will post 4.49 earnings per share for the current year.

Royalty Pharma Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th were issued a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a yield of 2.45%. The ex-dividend date of this dividend was Friday, May 16th. Royalty Pharma's dividend payout ratio is currently 47.57%.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.